Arolax Tablet, Syrup
Arolax Nebuliser Solution is a sterile, clear, colorless, preservative-free solution of the hydrochloride salt of Arolax, the (R)-enantiomer of the drug substance racemic salbutamol. Arolax Hydrochloride is a relatively selective &beta 2 adrenergic receptor agonist.
Activation of &beta 2 adrenergic receptors on airway smooth muscle leads to the activation of adenylcyclase and to an increase in the intracellular concentration of cyclic AMP. This increase in cAMP leads to the activation of protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation. Arolax relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Arolax acts as a functional antagonist to relax the airway irrespective of the spasmogen involved, thus protecting against all bronchoconstrictor.
Arolax tablet is used for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.
Arolax Nebuliser Solution or Inhaler is used for the treatment or prevention of bronchospasm in adults, adolescents, and children with reversible obstructive airway disease.
Arolax is also used to associated treatment for these conditions: Bronchospasm
|Other Names||(R)-salbutamol, Levalbuterol, Levosalbutamol, R-salbutamol|
|Weight||2mg, 1 mg, 1 mg/5ml|
plasma protein binding is relatively low.
|Therapeutic Class||Short-acting selective β2-adrenoceptor stimulants|
|Manufacturer||Navana Pharmaceuticals Ltd|
|Last Updated:||June 23, 2021 at 11:22 am|
Table Of contents
- Adults and children above 12 years: 1-2 mg three times daily.
- Children (6 -11 years): 1 mg three times daily.
- Adults and children above 12 years: 5-10 ml three times daily.
- Children (6 -11 years): 5 ml three times daily.
Arolax Nebuliser Solution-
This Nebuliser Solutionis supplied in unit-dose ampoules and requires no dilution before administration by nebulization.
- Children (6 months-11 years): The recommended dosage is 0.31 mg administered three times a day, by nebulization. Routine dosing should not exceed 0.63 mg three times a day.
- Adults and Adolescents above 12 years old: The recommended starting dosage is 0.63 mg administered three to four times a day, every 6 to 8 hours, by nebulization.
- Patients 12 years of age and older with more severe asthma or patients who do not respond adequately: 0.63 mg of Arolax Nebuliser Solution may benefit from a dosage of 1.25 mg three times a day.
You should take your Arolax Inhaler as needed for an asthma attack at any time of day, with or without food, by taking 1-2 puffs up to 4 times daily and no more than 8 puffs in 24 hours. If you are using your Arolax Inhaler more than 3-4 times a week this may indicate that your asthma is not well controlled and you may need to review your medication. You can also use your Arolax Inhaler to prevent allergy or exercise induced asthma by taking 2 puffs 15 minutes before exercise or exposure to a known allergen.
Potentially serious side effects like hypokalamia may result from ß-2 agonist therapy. This effect may be potentiated by hypoxia. The other likely side effects are gastrointestinal disturbances such as nausea, vomiting, burning substernal or epigastric pain and diarrhoea. In some cases nervousness, headache, dizziness, fatigue and sleeplessness may occur.
Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations. Oral Arolax should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias or hypertension. Arolax can be used with caution after myocardial infarction.
Arolax Hydrochloride, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, hypertension, and cardiac arrhythmias; in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines. Arolax Nebuliser Solution or Inhaler must not be injected.
Other short-acting sympathomimetic bronchodilators or epinephrine should be used with caution with Arolax. If additional adrenergic drugs are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects.
Food InteractionNo interactions found.
3.3 - 4 hours
Pregnancy & Breastfeeding use
Use in pregnancy: Use of oral Arolax in pregnant women should be considered only if the expected benefit to the mother is greater than any possible risk to the foetus or the infant.
Use in lactation: It is not known whether Arolax is excreted in human milk. Caution should be exercised when oral Arolax is administered to a nursing woman.
Pregnancy: There are no adequate and well-controlled studies of Arolax Nebuliser Solution in pregnant women. Arolax Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether Arolax is excreted in human milk. Caution should be exercised when Arolax Nebuliser Solution is administered to a nursing woman.
Arolax Nebuliser Solution is contraindicated in patients with a history of hypersensitivity to Arolax Hydrochloride or racemic salbutamol.
The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the symptoms listed under side effects e.g., tachycardia, nervousness, headache, tremor, nausea, dizziness, fatigue and sleeplessness. Hypokalaemia also may occur. Treatment consists of discontinuation of oral Arolax together with appropriate symptomatic therapy. In the event of serious poisoning, the stomach should be emptied and, if necessary, a beta-blocker administered with caution in patients with a history of bronchospasm.
Store at cool and dry place. Protected from light and moisture. Keep out of the reach of children.